KURAに登録されているコンテンツの著作権は、執筆者、出版社（学協会）などが有します。
KURAに登録されているコンテンツの利用については、著作権法に規定されている私的使用や引用などの範囲内で行ってください。
著作権法に規定されている私的使用や引用などの範囲を超える利用を行う場合には、著作権者の許諾を得てください。ただし、著作権者から著作権等管理事業者（学術著作権協会、日本著作出版権管理システムなど）に権利委託されているコンテンツの利用手続については、各著作権等管理事業者に確認してください。
Colchicine responsive chronic recurrent multifocal osteomyelitis with \textit{MEFV} mutations: A variant of familial Mediterranean fever?

Shimizu M MD PhD, Tone Y MD, Toga A MD, Yokoyama T MD, Wada T MD PhD, Toma T MD PhD and Yachie A MD PhD

Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University

13-1 Takaramachi, Kanazawa, 920-8641, Japan

Correspondence to Masaki Shimizu, M.D., Ph.D.,

Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa, 920-8641, Japan

Tel: +81-76-265-2314, Fax: +81-76-262-1866

E-mail: mshimizu@ped.m.kanazawa-u.ac.jp

Short title: Colchicine responsive chronic recurrent multifocal osteomyelitis with \textit{MEFV} mutations

Key message: The \textit{MEFV} gene might be associated with more than typical FMF.
Sir, Familial Mediterranean fever (FMF) is an autosomal recessive disease characterized by self-limited recurrent attacks of fever with serositis such as peritonitis, pleuritis and arthritis [1]. FMF is caused by mutations in MEFV gene [2]. This gene had been considered to be responsible only for FMF in the past, however, recent reports show that MEFV gene is associated with more than typical FMF and is linked to additional clinical presentations within the family of the autoinflammatory diseases [2-4]. Here, we describe a case of colchicine responsive chronic recurrent multifocal osteomyelitis (CRMO) with MEFV gene mutations.

A 14-year-old female was referred with fever of unknown origin persisting for 15 days. Physical examination was unremarkable. Laboratory findings showed normal white blood cell count (3.9 ×10⁹/L), high levels of CRP (3.1mg/dl), accelerated erythrocyte sedimentation rate (72mm/h), normal levels of immunoglobulins and negative autoantibodies. Blood culture was negative. Unexpectedly, gallium (Ga) scintigraphy on day 3 after admission demonstrated significant uptake in bilateral proximal region of tibia (Figure A). Plain radiography showed no significant findings (Figure D) but magnetic resonance imaging (MRI) demonstrated multifocal lesions whose intensity was low in T1 weighted condition, high in T2 weighted condition in bilateral tibia (Figure E). The biopsy of left tibia showed non-specific inflammatory changes and no
malignant cells. The culture of bone marrow was negative. She had severe pain of left heel on day 21. MRI on day 23 demonstrated multifocal lesions whose intensity was low in T1 weighted condition, high in T2 weighted condition in bilateral tarsal bones (Figure F). Ga scintigraphy on day 38 demonstrated significant uptake in left calcaneus and bilateral femur (Figure B). From these findings, the diagnosis of multifocal recurrent osteomyelitis was made. No evidence of bone destruction or hyperostosis was observed at the time of diagnosis. High fever continued despite the treatment with appropriate antibiotics and naproxen for 8 weeks. However, she was relieved dramatically from high fever soon after colchicine (2mg/day) was started. The mutation analysis demonstrated the heterozygous mutation of E148Q-P369S-R408Q in cis on one allele of MEFV gene. But no mutation was found in LPIN2 gene. Colchicine dose was gradually decreased to 0.5mg/day and daily colchicine therapy (0.5mg/day) relieved her from febrile attacks for 1 year, although she had one episode of osteomyelitis in left fibula (Figure C) when the patient ceased to take colchicine.

FMF is an autosomal recessive, inherited periodic inflammatory syndrome, characterized by self-limited recurrent attacks of fever with serositis such as peritonitis, pleuritis and arthritis [1]. The disease is common among people coming from eastern Mediterranean ancestry. The mainstay of treatment is colchicine which is effective for
both relieving symptoms and preventing secondary amyloidosis. MEFV gene encodes a protein named pyrin, which is expressed in neutrophils and monocytes. The function of pyrin is still unknown and remains to be determined.

MEFV gene had been considered to be responsible only for FMF in the past. However, about one-third of patients with FMF have a single mutation on one allele. This finding suggests that FMF might be transferred as an autosomal dominant trait with partial penetration. Another possibility is that an additional, unidentified gene might be associated with the disease in these patients with single allele mutation.

Recently it has been reported a case with heterozygous MEFV mutations and distinct clinical presentations not typical for FMF, colchicine responsive recurrent episodes of muscle pains [3]. These reports including our case show MEFV gene is associated with more than a single disease (FMF) and is linked to additional clinical presentations within the family of the autoinflammatory diseases [4,5] and some rheumatic diseases such as s-JIA[6,7].

The mutation analysis in our patient demonstrated the heterozygous mutation of E148Q-P369S-R408Q. In the whole list of 186 sequence alterations reported in Infevers - an online database for autoinflammatory mutations available at http://fmf.igh.cnrs.fr/ISSAID/infevers [8], this mutation is reported to be associated with
atypical clinical presentations for FMF.

CRMO is an ill-defined inflammatory disease. In typical cases, multiple bone lesions with apparent bone destruction, hyperostosis and pustulosis of the skin are seen [9]. But there are variable clinical manifestations, which make differential diagnosis of CRMO often difficult. LPIN2 mutation is detectable in a syndrome form of CRMO known as Majeed syndrome [10], but for most cases responsible gene is unknown. CRMO is unusual, or unexpected manifestation for FMF, and this is the first case of CRMO with MEFV mutations to our knowledge. To start the treatment with colchicines promptly, thereby relieving symptoms and preventing secondary amyloidosis, the mutation analysis of MEFV gene should be performed in cases of CRMO.

Acknowledgements

Disclosure statement: The authors have declared no conflicts of interest.

References


10. Ferguson PJ, Chen S, Tayeh MK, Ochoa L, Leal SM, Pelet A, Munnich A,

Figure legends

A-C: Gallium scintigraphy: the image on day3 (A) showing significant uptake in bilateral proximal region of tibia. day38 (B) showing significant uptake in left calcaneus and bilateral femur. 9 months later (C) showing significant uptake in left fibula. D: A plain X-ray, frontal view, showed no significant findings including sclerosis in bilateral tibia. E, F: Magnetic resonance imaging: the T1-weighted image on day3 (E) showing multiple lesions whose intensity was low in bilateral tibia. The T2-weighted image on day 23 (F) showing multiple lesions whose intensity was high in bilateral tarsal bones